This expert discussion from the 2011 Annual Hematology Meeting in San Diego focuses on the following data releases:

Abstract 278: Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT-I

Abstract 795: Health-related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy

Abstract 793: Comparison of outcomes of advanced myelofibrosis patients treated with ruxolitinib to those of a historical control group: Survival advantage of ruxolitinib therapy

Abstract 280: Complete hematological, molecular and histological remissions without cytoreductive treatment lasting after pegylated-interferon α-2a therapy in polycythemia vera: Long term results of a phase 2 trial

Abstract 282: Results of a phase 2 study of pacritinib (SB1518), a novel oral JAK2 inhibitor, in patients with primary, post-polycythemia vera, and post-essential thrombocythemia myelofibrosis